2023
2604. Contact With School-Aged Children is a Major Risk Factor for Pneumococcal Colonization in Older Adults
Wyllie A, Yolda-Carr D, Hislop M, Mbodj S, Kennedy H, McLaughlin M, Wurst L, Waghela P, Peno C, Alexander-Parrish R, Arguedas A, Gessner B, Weinberger D. 2604. Contact With School-Aged Children is a Major Risk Factor for Pneumococcal Colonization in Older Adults. Open Forum Infectious Diseases 2023, 10: ofad500.2218. PMCID: PMC10679235, DOI: 10.1093/ofid/ofad500.2218.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineOlder adultsTime pointsRisk factorsPneumococcal colonizationAdult transmissionTransmission of pneumococciMajor risk factorRecent contactYear oldsNon-institutionalized individualsYears of ageGrant/research supportSame time pointsPneumococcal acquisitionConjugate vaccineSchool-Aged ChildrenElevated prevalenceYoung school-age childrenHealth statusYoung contactsSaliva samplesMedical directorsSample adultsPneumococci
2017
Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi
Chaguza C, Cornick JE, Andam CP, Gladstone RA, Alaerts M, Musicha P, Peno C, Bar-Zeev N, Kamng'ona AW, Kiran AM, Msefula CL, McGee L, Breiman RF, Kadioglu A, French N, Heyderman RS, Hanage WP, Bentley SD, Everett DB. Population genetic structure, antibiotic resistance, capsule switching and evolution of invasive pneumococci before conjugate vaccination in Malawi. Vaccine 2017, 35: 4594-4602. PMID: 28711389, PMCID: PMC5571440, DOI: 10.1016/j.vaccine.2017.07.009.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBacterial CapsulesChildChild, PreschoolDrug Resistance, Multiple, BacterialEvolution, MolecularFemaleGenome, BacterialHigh-Throughput Nucleotide SequencingHumansInfantInfant, NewbornMalawiMalePneumococcal InfectionsPneumococcal VaccinesPrevalenceRetrospective StudiesSerogroupSerotypingStreptococcus pneumoniaeVaccinationVaccines, ConjugateYoung AdultConceptsPneumococcal conjugate vaccineMDR ratePneumococcal isolatesHigher MDR rateImplementation of PCV13Prevalence of serotypesNon-vaccine serotypesInvasive pneumococcal isolatesGood infection preventionAntibiotic resistance ratesAntibiotic resistanceAbsence of vaccinesReplacement serotypesSerotype replacementInvasive pneumococciPneumococcal infectionConjugate vaccineSerotype 12FDisease burdenInfection preventionSerotype prevalenceHigh prevalenceInvasive isolatesContinued surveillanceResistance rates